Efficacy of osmoprotectants on prevention and treatment of murine dry eye

W Chen
X Zhang
J Li
Y Wang
Q Chen

See next page for additional authors

Follow this and additional works at: https://researchonline.nd.edu.au/med_article

Part of the Medicine and Health Sciences Commons

This article was originally published as:

Original article available here:
http://iovs.arvojournals.org/article.aspx?articleid=2128072

This article is posted on ResearchOnline@ND at https://researchonline.nd.edu.au/med_article/781. For more information, please contact researchonline@nd.edu.au.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non-Commercial No Derivatives 4.0 International license (CC BY-NC-ND 4.0), which permits others to copy and redistribute the material in any medium or form, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by-nc-nd/4.0/

This article which was originally published in *Investigative Ophthalmology and Visual Science* available at: http://iovs.arvojournals.org/article.aspx?articleid=2128072

Efficacy of Osmoprotectants on Prevention and Treatment of Murine Dry Eye

Wei Chen,¹ Xin Zhang,¹ Jinyang Li,¹ Yu Wang,¹ Qi Chen,¹ Chao Hou,¹ and Qian Garrett²,³

¹School of Ophthalmology and Optometry, Wenzhou Medical College, Wenzhou, China
²Brien Holden Vision Institute, Sydney, Australia
³School of Optometry and Vision Science, University of New South Wales, Sydney, Australia

Correspondence: Qian Garrett, Brien Holden Vision Institute, Level 4, Rupert Myers Building, The University of New South Wales, Sydney, NSW 2052, Australia; q.garrett@brienholdenvision.org.

WC and XZ contributed equally to the work presented here and should therefore be regarded as equivalent authors.

Submitted: March 22, 2013
Accepted: August 14, 2013


Purpose. To evaluate the efficacy of osmoprotectants on prevention and treatment of dry eye in a murine model.

Methods. Dry eye was induced in mice by using an intelligently controlled environmental system (ICES). Osmoprotectants betaine, L-carnitine, erythritol, or vehicle (PBS) were topically administered to eyes four times daily following two schedules: schedule 1 (modeling prevention): dosing started at the beginning of housing in ICES and lasted for 21 or 35 days; schedule 2 (modeling treatment): dosing started after ICES-housed mice developed dry eye (day 21), continuing until day 35. Treatment efficacy was evaluated for corneal fluorescein staining; corneal epithelial apoptosis by TUNEL and caspase-3 assays; goblet cell numbers by PAS staining; and expression of inflammatory mediators, TNF-α, IL-17, IL-6, or IL-1β by using RT-PCR on days 0, 14, 21, and/or 35.

Results. Compared with vehicle, prophylactic administration of betaine, L-carnitine, or erythritol significantly decreased corneal staining and expression of TNF-α and IL-17 on day 21 (schedule 1). Treatment of mouse dry eye with osmoprotectants significantly reduced corneal staining on day 35 compared with day 21 (schedule 2). Relative to vehicle, L-carnitine treatment of mouse dry eye for 14 days (days 21 to 35) resulted in a significant reduction in corneal staining, number of TUNEL-positive cells, and expression of TNF-α, IL-17, IL-6, or IL-1β, as well as significantly increased the number of goblet cells.

Conclusions. Topical application of betaine, L-carnitine, or erythritol systematically limited progression of environmentally induced dry eye. L-carnitine can also reduce the severity of such dry-eye conditions.

Keywords: L-carnitine, betaine, osmoprotectants, dry eye, animal model, apoptosis, inflammation, TNF-α, IL-17, IL-6, IL-1β

Dry-eye disease is one of the most common ophthalmic pathologies and is associated with tear film hyperosmolarity and inflammation of the ocular surface.¹ Osmolarity has been reported to be highly correlated with severity of the disease across normal, mild/moderate, and severe categories² and can reach values of up to 360 mOsm³,⁴ compared with normal tear film, which ranges between 300 and 310 mOsm.⁵ It has been proposed that the tear film osmolarity over the ocular surface can reach much higher values than is measured in meniscus,⁶ and may reach values of up to 600 mOsm.⁷ Under a hyperosmolar environment, cells will lose water and/or gain salts, with concomitant changes in cell volume,⁸ leading to damage to DNA and proteins,¹⁰ and induction of ocular surface inflammatory responses.¹¹ Tear film hyperosmolarity induces hyperosmolarity of epithelial cells, unleashing a cascade of inflammatory cytokines, such as IL-1, IL-6, IL-8, and TNF-α; and proteolytic enzymes, such as matrix metalloproteinase-9 (MMP-9).¹²,¹³ The production of inflammatory mediators on the ocular surface has been suggested as the primary cause of ocular discomfort, inflammation, and ocular surface cell apoptosis.¹⁴

Hyperosmolarity-induced corneal epithelial apoptosis has been observed using both cultured human ocular surface epithelial cells and animal dry-eye models.¹⁵,²¹ Generally, cells can adapt to a hyperosmotic environment by accumulating compatible organic osmolytes/osmoprotectants.²² Osmoprotectants, such as L-carnitine and betaine, are compatible solutes that act similarly to electrolytes to balance osmotic pressure yet do not interfere with cell metabolism and can aid survival of cells under extreme osmotic stress.⁹ L-carnitine and erythritol have been shown to protect human corneal epithelial cells in hyperosmotic conditions and to lower levels of mitogen-activated protein (MAP) kinases in response to hyperosmolar stress.²³ L-carnitine and betaine also stabilize corneal epithelial cell volume under hyperosmotic stress and ameliorate hyperosmotic stress-induced human corneal epithelial cell apoptosis (Garrett Q. IOVS 2012;53:ARVO E-Abstract 564; Willcox MD. IOVS 2012;53:ARVO E-Abstract 564).²⁴ Further, in dry-eye patients, reduced levels of tear L-carnitine compared with healthy subjects have been reported,²⁵ suggesting that carnitine might play a contributory role in the development of dry eye.

The intelligently controlled environmental system (ICES)-induced murine dry eye model has been used previously to assess therapeutic effects of trehalose eye drops.¹⁵,²⁶ Continual exposure of mice to the low humidity and excessive air flow...
created in ICES for 14 or more days promotes tear evaporation that destabilizes the tear film and increases tear osmolarity, showing biological and morphologic characteristics of dry eye similar to those in humans, such as reduced aqueous tear production, presence of corneal epithelial defects and apoptosis of ocular surface epithelium, increased inflammatory responses and expression of proteolytic MMP-9, as well as a decrease in the number of goblet cells.\textsuperscript{15,26,27} Using this animal model, the present study extended the previous in vitro studies of osmoprotectants (Garrett Q. IOVS 2012;53:ARVO E-Abstract 564; Willcox MD. IOVS 2012;53:ARVO E-Abstract 564)\textsuperscript{23,24} to determine the efficacy of osmoprotectants L-carnitine, betaine, and erythritol in protection and therapeutic treatment of ICES-induced murine dry eye.

### Table. The Primer Sequences Used for qRT-PCR

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Primer, 5′–3′</th>
<th>Reverse Primer, 5′–3′</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1β</td>
<td>TGAGCTGAAGCTTCCACC</td>
<td>CTGATGAGCTTGGGGAA</td>
</tr>
<tr>
<td>IL-6</td>
<td>AGATACAGAAAGAGACCCAGTC</td>
<td>GCGTATGAAATTTGCTAGGAAG</td>
</tr>
<tr>
<td>IL-17</td>
<td>CCTAAGGCTATTCGCAACCCT</td>
<td>CCACGTTGCTCCGTGATT</td>
</tr>
<tr>
<td>TNF-α</td>
<td>TCTACTGAGACCTGGTTGTCG</td>
<td>ACGTGCGTACAGCTGGTC</td>
</tr>
<tr>
<td>GAPDH</td>
<td>TGTCGCTGTCGATCCGAC</td>
<td>CCTGCTTCACCACCTTCG</td>
</tr>
</tbody>
</table>

**Figure 1.** Mean corneal staining score of mice in response to housing at ICES and topical treatment with betaine (0.23% in PBS), carnitine (0.25% in PBS), erythritol (0.25% in PBS), or vehicle PBS, and ICES with no treatment, on days 0, 14, 21, and/or 35. (A) Schedule 1: compounds were administered to mice at the beginning of their housing in ICES. *Statistically significant difference (P < 0.05) compared with the vehicle (PBS) treatment on the same day (n = 22 for days 14 and 21; n = 10 for day 35). (B) Schedule 2: compound administration following housing in ICES for 21 days while mice were housed in ICES for a total of 35 days. *Statistically significant difference (P < 0.05) between day 21 and day 35 for the same treatment group; #Statistically significant difference (P < 0.05) compared with the vehicle (PBS) treatment on day 35 (n = 18). Error bars present the SD. (C, D) Representative corneal staining images after the treatment ([a], betaine; [b], L-carnitine; [c], erythritol; [d], PBS; or [e], ICES with no treatment) for schedule 1, day 21 (C) or schedule 2, day 35 (D).
MATERIALS AND METHODS

Animals

All procedures were approved by the Animal Care and Ethics Committee of Wenzhou Medical College, Zhejiang, China, and adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Female C57BL/6 mice (age range, 4–6 weeks, supplied by the Animal Breeding Unit of Wenzhou Medical College) were used for this study. Only those healthy mice with no corneal infections, infiltrations, or leukoma, and with total scores of corneal fluorescein staining less than 10 were selected for the study.

ICES-Induced Murine Dry Eye Model

A murine model of dry eye was induced by an ICES. The animals were maintained in relative humidity, 60% to 80%, no airflow, and at 21 to 23°C. Dry-eye desiccation was created through exposure to relative humidity of 13.1 ± 3.5%, airflow of 2.2 ± 0.2 m/s, and temperature of 22 ± 2°C. After housing for 21 days, mice began developing dry-eye conditions similar to those observed in humans. The relative humidity and temperature of ICES were monitored daily.

Compound Administration Schedules

Osmoprotectants for topical administration of betaine, L-carnitine, and erythritol were formulated in sterile PBS. Mice without any topical treatment were used as the dry-eye control group (ICES), whereas PBS-treated mice were the vehicle control (PBS). Two topical administration schedules were used for this study: schedule 1 was designed to model prevention in which dosing of a compound started at the beginning of housing in the ICES (on day 1) and lasted for 21 or 35 days; whereas schedule 2 was to model treatment where dosing started on day 22 after the housed mice developed dry eye (on day 21) and lasted until day 35. During both schedules, mice remained housed in ICES. In both schedules, 10 µL per eye of each compound solution was topically administered to mice eyes bilaterally four times a day. Five treatment groups were classified as follows: betaine (0.23% in PBS), L-carnitine (0.25% in PBS), erythritol (0.25% in PBS), PBS only, and no treatment (ICES), respectively. Five animals were used per treatment group. PBS was from Maixin Technology (Fujian, China) and betaine, L-carnitine, erythritol were all from Sigma-Aldrich (Shanghai, China). The concentrations of the test compounds were determined based on the previously published data where addition of L-carnitine (10–15 mM), erythritol (20–40 mM), or betaine (10 mM), to hyperosmolar media demonstrated osmoprotection of cultured human corneal epithelial cells. As well, the addition of betaine or L-carnitine at 10 mM, or erythritol at 40 mM, to the culture medium had no effect on viability of the cultured corneal epithelial cells.

Clinical Examination: Corneal Fluorescein Staining

Clinical examination using corneal fluorescein staining was performed on all eyes on days 0, 14, 21, and 35 by instilling via a micropipette 0.5 µL of 5% fluorescein PBS solution into the inferior conjunctival sac. The cornea was examined using a slit-lamp microscope (SLM-3; Kanghua Technology Co., Ltd., Chongqing, China) with cobalt blue light after fluorescein instillation. The stained area was assessed and graded by a masked observer using the 2007 Dry Eye WorkShop (DEWS)-recommended grading system. Mouse corneas were rated from 0 to 4, with the cornea surface divided into five regions (0 dot, Grade 0; 1–5 dots, Grade 1; 6–15 dots, Grade 2; 16–30 dots, Grade 3; and 30 dots, Grade 4). The total score from the five regions was recorded.

Animal Euthanasia

For schedule 1, at the end time point of day 21 in ICES (schedule 1, day 21), mice from each group were killed with an overdose of a mixture of ketamine and xylazine for histological, immunohistochemical, and quantitative RT-PCR (qRT-PCR). For schedule 2, a subset of mice from ICES control was killed at day 21 and other mice were killed on day 35 (schedule 2, day 35). Additional healthy animals not housed in ICES and receiving no treatment were euthanized as untreated healthy controls for comparison.

FIGURE 2. Corneal epithelium of the normal healthy mice or the ICES-housed mice with or without the treatment with betaine (A), L-carnitine (B), erythritol (C), PBS (D), or with no treatment (E), for schedule 1, day 21 and schedule 2, day 35 (magnification: ×40).
PAS Staining of Goblet Cells

After animals were killed, eyes and ocular adnexa were surgically excised, fixed in 10% formalin, paraffin embedded, and cut into 8-μm sections. The bulbar conjunctival epithelium (superior and inferior regions) sections were stained with PAS (Sigma-Aldrich) reagent for measuring goblet cells and were examined and photographed with a microscope equipped with a digital camera (BX51; Olympus, Guangzhou, China). PAS-positive goblet cells in the conjunctiva were measured in five sections from each eye with image analysis software (available in the public domain at http://rsb.info.nih.gov/ij/index.html; ImageJ software; developed by Wayne Rasband, National Institutes of Health, Bethesda, MD).

Apoptosis

Immunohistochemical evaluation of caspase-3 expression and TUNEL assay were performed on corneal tissues collected on schedule 1, day 21, and schedule 2, day 35, to detect apoptosis of the corneal epithelial cells. The expression of caspase-3 was evaluated by laser scanning confocal microscopy (LSM 710; Zeiss with krypton-argon and He-Ne laser; Carl Zeiss Meditec, Sartrouville, France) using frozen corneal tissue sections. Mice eyes (schedule 1, day 21, and schedule 2, day 35) from each treatment group were excised. Corneal section slides were fixed with methanol at 4°C for 10 minutes. After fixation, they were permeabilized with Triton X-100 (0.25% in PBS; Sigma, St. Louis, MO) for 10 minutes. Caspase-3 antibody (1:100 dilution; Abcam, Cambridge, MA) was applied and incubated for 1 hour at room temperature. Counterstaining with 4′,6-diamidino-2-phenylindole (DAPI; 1:1000 dilution) was followed for 10 minutes. Sections were covered with SlowFade antifade mounting medium (Invitrogen, Eugene, OR) and sealed with a cover slip for microscopic observation.

DNA fragmentation detected by TUNEL assay was also evaluated using laser scanning confocal microscopy and frozen corneal tissue sections. Mice eyes (schedule 1, day 21, and schedule 2, day 35) from each treatment group were excised. Corneal section slides were fixed with methanol at 4°C for 10 minutes. After fixation, they were permeabilized with Triton X-100 (0.25% in PBS; Sigma, St. Louis, MO) for 10 minutes. DNA fragmentation was detected by TUNEL assay using a TUNEL Kit (In Vitro Detection Kit III; Roche Diagnostics, Mannheim, Germany) and analyzed using a laser scanning confocal microscope (LSM 710; Zeiss with krypton-argon and He-Ne laser; Carl Zeiss Meditec, Sartrouville, France) using frozen corneal tissue sections. Mice eyes (schedule 1, day 21, and schedule 2, day 35) from each treatment group were excised. Corneal section slides were fixed with 4% paraformaldehyde in PBS at room temperature for 10 minutes. After fixation, they were permeabilized with Triton X-100 (0.1% in PBS; Sigma, St. Louis, MO) for 10 minutes. DNA fragmentation was detected by TUNEL assay using a TUNEL Kit (In Vitro Detection Kit III; Roche Diagnostics, Mannheim, Germany) and analyzed using a laser scanning confocal microscope (LSM 710; Zeiss with krypton-argon and He-Ne laser; Carl Zeiss Meditec, Sartrouville, France) using frozen corneal tissue sections. Mice eyes (schedule 1, day 21, and schedule 2, day 35) from each treatment group were excised. Corneal section slides were fixed with 4% paraformaldehyde in PBS at room temperature for 10 minutes. After fixation, they were permeabilized with Triton X-100 (0.1% in PBS; Sigma, St. Louis, MO) for 10 minutes.
Louis, MO) for 10 minutes and then 50 μL (5 μL enzyme solution in 45 μL label solution) TUNEL reaction mixture (In Situ Cell Death Detection Kit; Roche, Mannhein, Germany) was applied and incubated for 1 hour at 37°C in a humidified atmosphere. Counterstaining with DAPI (1:1000 dilution) was followed for 30 minutes. Sections were covered with antifade mounting medium and sealed with a cover slip for microscopic observation.

Inflammatory Responses

qRT-PCR was used for detection of the expression of IL-1β, IL-6, IL-17, TNF-α, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Total RNA from conjunctivas was extracted and pooled from two eyes of the same experimental group and same compound administration schedule using the RNA isolation kit according to the manufacturer’s instructions (PicoPure RNA isolation kit; Applied Biosystem, Foster City, CA). cDNA was synthesized from 1 μg total RNA using random primers and Moloney Murine Leukemia Virus (M-MuLV) reverse transcriptase. The primer sequences for qRT-PCR detection of the inflammatory mediators of interest are listed in the Table.

The RNA concentration was measured at 260 nm and stored at −80°C before use. qRT-PCR analysis was employed by using the SYBR Green PCR Core Reagents System (Applied Biosystems, Paisley, UK) and Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems). Assays were performed in duplicate and repeated three times. The qRT-PCR results were analyzed using the comparative threshold cycle method and normalized with GAPDH as an endogenous reference.

Statistical Analysis

The 2-(Delta Delta C[T]) method\textsuperscript{29} was used to analyze the relative changes in gene expression from real-time RT-PCR experiments. Statistical comparisons of four treatment groups and the group without treatment (ICES) for real-time PCR were performed with ANOVA. Post hoc multiple comparisons were adjusted using Tukey correction. The Mann-Whitney U test was used to compare the controls and the treatment groups for mouse corneal fluorescein staining scores. P less than 0.05 was considered statistically significant. Analyses were performed using SPSS 13.0 software (IBM SPSS Statistics, IBM Corporation, Chicago, IL).
**RESULTS**

**Corneal Fluorescein Staining**

Fluorescein staining was used to assess changes in corneal epithelial integrity. For schedule 1, all three osmoprotectants (betaine, L-carnitine, or erythritol) reduced corneal staining on day 21 compared with the vehicle PBS and the ICES control receiving no treatment \((P < 0.05)\) (Figs. 1A, 1C). Reduced corneal staining was also evident on day 14 for betaine- or L-carnitine-treated mice; on day 35, L-carnitine treated mice corneas still exhibited significantly lower staining compared with the PBS control and ICES (Figs. 1A, 1C).

For schedule 2, Figures 1B and 1D show mouse corneas treated with betaine, L-carnitine, or erythritol for 14 days, following 21 days of desiccating conditions (by which time mice displayed typical signs of dry eye). All compounds demonstrated therapeutic action with significant reductions in mean corneal staining on day 35 compared with day 21 \((P < 0.05)\).
Corneas treated with L-carnitine or erythritol showed significant reduction in mean corneal staining relative to vehicle PBS on day 35. Betaine showed some effect in reducing corneal staining, but the effect was not significantly different compared with PBS ($P = 0.252$) on day 35. No statistically significant difference was found between PBS and ICES on day 21 or day 35.

**Morphology of the Corneal Epithelium**

Corneal epithelium thinning in the mice eyes after housing in ICES for 21 or 35 days was observed (Fig. 2E) compared with the normal healthy mice eyes (Fig. 2 normal). Although slight thinning was observed in all the treatment groups (Figs. 2A–D) for both schedule 1, day 21, and schedule 2, day 35, the ICES-housed, untreated mice showed greater thinning compared with the treatment or normal mice: from $32.7 \pm 1.1 \mu m$ to $24.3 \pm 2.1 \mu m$ and $23.5 \pm 1.2 \mu m$ (normal to ICES housed) for schedule 1, day 21, and schedule 2, day 35, respectively.

**Conjunctival Goblet Cells**

For both schedule 1, day 21 (Fig. 3 [I]) and schedule 2, day 35 (Fig. 3 [II]), there was a significant reduction in the number of goblet cells for all the ICES-housed mice (with or without treatments) compared with normal healthy mice that had not been housed in ICES or received any treatment (all $P < 0.05$). The ICES-housed mice presented with increased numbers of goblet cells after receiving the treatment with betaine, L-carnitine, or vehicle PBS relative to those with no treatment (Fig. 3, all $P < 0.05$). Although an increasing trend in goblet cell number was observed with betaine or erythritol, only L-carnitine treatment showed significantly increased goblet cell numbers compared with the vehicle PBS control (Fig. 3, $P = 0.0001$ [superior], $0.0002$ [inferior] for schedule 1, day 21, and $P = 0.0001$ [superior and inferior] for schedule 2, day 35, respectively).

**Apoptosis: Caspase-3 Expression**

Immunohistochemistry for caspase-3 expression (green staining) in the corneal epithelium revealed much reduced immunoreactivity (similar to the level in normal healthy mice) under schedule 1 following daily treatment with each osmoprotectant, betaine (A), L-carnitine (B), or erythritol (C), compared with the treatment vehicle PBS (D), or with no treatment (ICES, E) (Fig. 4 [I]). For schedule 2, on day 35, the L-carnitine–treated mice (Fig. 4 [IIB]) presented similar immune reactivity of caspase-3 compared with the normal healthy mice, whereas for betaine (A), erythritol (C), or ICES (E), immune reactivity of caspase-3 was not reduced relative to PBS control.

**Apoptosis: TUNEL Staining**

Figure 5 shows that all the ICES-housed mice, with or without treatment, had a significantly higher number of apoptotic cells (positive to TUNEL staining; green) compared with the unhoused normal healthy mice on day 21, schedule 1 and day 35, schedule 2 (all $P < 0.05$). Furthermore, a significant reduction in the number of ICES-induced apoptotic cells was observed by day 21, schedule 1, in corneas that had received daily administration of the osmoprotectants or PBS vehicle (Fig.
There was a further reduction, relative to PBS, in apoptotic cell density with all the osmoprotectant treatments on day 21, schedule 1, and on day 35, schedule 2; however, this reduction reached statistical significance only for the L-carnitine treatment group (P = 0.032 and 0.0005, Fig. 5 [I] and [II], respectively).

**Inflammatory Responses**

qRT-PCR was used to evaluate TNF-α, IL-17, IL-6, and IL-1β mRNA expression levels (Fig. 6 for schedule 1, day 21; Fig. 7 for schedule 2, day 35). For both schedules, mRNA expression for each inflammatory mediator was significantly higher in the conjunctiva of all the ICES-housed mice than those in the unhoused normal healthy mice (P < 0.01, Figs. 6, 7). L-carnitine treatment in both schedules showed a statistically significant reduction in expression level of each mediator, relative to the vehicle PBS samples, as well as to the other treatment groups, betaine and erythritol (all P < 0.05, Figs. 6, 7). Furthermore, compared with the ICES control with no treatment, systematic administration of osmoprotectants (betaine, L-carnitine, or erythritol) significantly reduced the expression level of TNF-α, IL-17, IL-6, and IL-1β (Fig. 6, all P < 0.05). Compared with the vehicle PBS, expression of TNF-α and IL-17 was significantly reduced by the treatment with each osmoprotectant (Fig. 5, all P < 0.05). For schedule 2, day 35, treatment with each of the osmoprotectants significantly reduced expression of TNF-α, IL-17, and IL-6 compared with the ICES control with no treatment (Fig. 7, all P < 0.05). Betaine, L-carnitine, or erythritol treatment also significantly reduced TNF-α expression relative to vehicle PBS (Fig. 7, P < 0.05), but not the expression of IL-17, IL-6, and IL-1β.

**DISCUSSION**

In the present study, we used a murine dry eye model to evaluate the efficacy of prophylactic and therapeutic treatment of L-carnitine, betaine, and erythritol in maintaining and restoring ocular surface health in a desiccating environment created by ICES. We showed that systematic administration with these compounds during the establishment of murine dry eye (by housing in ICES) limited desiccation-induced clinical signs of dry eye, ocular surface inflammatory responses, and apoptosis. We also showed that on onset of mouse dry-eye conditions, systematic treatment with L-carnitine, or to a lesser extent, with betaine or erythritol, attenuated the deleterious effects by reduction of corneal staining, ocular epithelial cell apoptosis, and expression of TNF-α, IL-17, IL-6, and IL-1β, as well as maintaining the number of PAS-positive conjunctival goblet cells, thus demonstrating the potential of L-carnitine not only in the prevention but also in the therapeutic treatment of dry eye.

Epitheliopathy is one of the most easily recognizable clinical features of dry-eye disease. Environmental desiccation stress-induced dry-eye conditions decrease epithelial cell size and increase epithelial cell turnover. Staining the ocular surface with diagnostic dyes, such as fluorescein, provides a practical method for evaluating ocular surface integrity. Treatment with betaine, L-carnitine, or erythritol during the development of
L-carnitine is essential in maintaining the health of cells and is best known for its important role in the mitochondrial oxidation of long-chain fatty acids. Reports further indicate that L-carnitine also possesses anti-inflammatory and immunosuppressive activities. An in vivo study using a murine model of Crohn’s disease revealed that systemic administration/treatment with L-carnitine during the establishment of colonic inflammation successfully reduced cytokine production and intestinal inflammation, and this protection was associated with a suppressive effect of L-carnitine on the colonic mRNA expression and serum of IL-1β and IL-6. In humans, an immunosuppressive role of L-carnitine is also observed with reduction of TNF-α levels in surgical and AIDS patients after receiving L-carnitine supplementation. Like L-carnitine, betaine has also been reported to possess anti-inflammatory properties. Although the molecular events associated with the anti-inflammatory effects of L-carnitine or betaine in dry eye are not yet fully understood, we have demonstrated these activities also play a role in prevention and treatment of murine dry eye.

Long-term exposure of eyes to a desiccating environment increases tear evaporation, leading to hyperosmolarity. In an experimental mouse model of dry eye disease, desiccating stress increased mouse tear osmolarity nearly 2-fold. Hyperosmolarity is known to induce ocular surface epithelial injury. As both in vitro and experimental mouse models of dry eye are already developed (housing in ICES for 21 days) before treatment, the mice whose condition of dry eye was already developed (housing in ICES for 21 days) before treatment were not used because it could be argued that systematic administration of osmoprotectants L-carnitine, betaine, or erythritol can limit ocular surface inflammation. It is recognized that inflammation plays a prominent role in the development and magnitude of signs and symptoms of dry eye. Tear hyperosmolarity and intracellular signaling pathway activation induced by desiccating stress initiate the production of proinflammatory cytokines, such as IL-1, IL-6, IL-8, and TNF-α, and proteolytic enzymes, such as MMP-9. Using the same ICES murine dry-eye model, we previously reported dry-eye-associated increased ocular surface inflammation (a hallmark of dry-eye disease) as indicated by increased expression of IL-1β, TNF-α, IL-6, and IL-17. Application of trehalose eye drop restored ocular integrity in this model, reducing expression of IL-17, which in turn reduced the IL-17-mediated expression of IL-1, TNF-α, and IL-6. That TNF-α, IL-17, IL-6, and IL-1β were similarly upregulated in ICES controls in the present study further supports the use of the ICES model to mimic physiological stress experienced in dry eye. Activated MAP kinases can initiate expression of transcription factors, leading to expression of inflammatory cytokines, chemokines, and MMPs. Epithelial and inflammatory cell production of MMP-9, stimulated by IL-1 and TNF-α, is suggested to impede reepithelialization of the cornea after injury. Previous studies have shown the osmoprotectants L-carnitine and erythritol, alone or in combination, can reduce the activation/phosphorylation of MAP kinases in cultured human corneal epithelial cells in response to hyperosmolar stress. Reduced expression of MAP kinases would reduce production of MMP-9, suppressing the innate immune responses associated with expression of IL-1, TNF-α, and IL-17. In the present study, continual treatment of mice with betaine, L-carnitine, or erythritol suppressed expression of proinflammatory cytokines during the development of dry eye, as well as in dry-eye mice whose dry-eye conditions were developed before the treatment. This indicates that these compounds were able to at least partially ameliorate the inflammatory responses, consistent with previous reports of the anti-inflammatory properties of L-carnitine and betaine. It should be noted that among all the compounds, L-carnitine presented the only statistically significant, and the most beneficial effect, on lowering inflammatory responses of all the mediators investigated and demonstrated in both schedules.

Acknowledgments

The authors thank Judith Flanagan (Brien Holden Vision Institute) and Haixia Liu (Allergan) for their review of the manuscript. Supported by Allergan, Inc., and research grants from National Natural Science Foundation of China (81170820 [WC, QG]) and...
Ophthalmology & Visual Science

Zhejiang Provincial Natural Science Foundation of China (Y2090821 [WC]; QL12H12002 [QC]).

Disclosure: W. Chen, None; X. Zhang, None; J. Li, None; Y. Wang, None; Q. Chen, None; C. Hou, None; Q. Garrett, Allergan Inc. (F), P

References
37. Barchowsky A, Flrleta D, Vincenti MP. Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-